Phaseline

Companies › Precision BioSciences

Precision BioSciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Psychiatry, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PBGENE-HBV
In vivo gene editing via ARCUS platform targeting HBV cccDNA and integrated HBV DNA
–Phase 1HEPATITIS B CHRONICDec 2026
PBGENE-DMD
Ex vivo gene editing therapy targeting DMD mutations amenable to exons 45-55 excision
DMDPhase 1Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMDNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06680232PBGENE-HBVPhase 1HEPATITIS B CHRONICInfectious diseaseDec 2026
NCT07429240PBGENE-DMDPhase 1Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMDPsychiatryNov 2029

From the company's SEC filings

Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $54m a year; runway about 18 months at that burn, to Apr 2028

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DMD (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.